Q1. How many patients has your trust treated (for any disease) in the last 6 months with the following treatments:
a. Doptelet (avatrombopag)
b. Jakavi (ruxolitinib)
c. Nplate (romiplostim)
d. Revolade (eltrombopag)
e. Tavlesse (fostamatinib)
f. Hydroxycarbamide
Q2. In the last 6 months, how many patients has your trust treated for:
a. Immune thrombocytopenia (ICD10 code D69.3)
b. Myelofibrosis (ICD10 code D47.4)
c. Myelofibrosis (ICD10 code D47.4) – patients over the age 65
Q3. Of the patients treated for immune thrombocytopenia (ICD10 code D69.3) in the last 6 months, how many were treated with:
a. Mycophenolate mofetil
b. Rituximab
c. Surgery (splenectomy)
Q4. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?
a. Of the myelofibrosis patients diagnosed in the last 3 years, how many were treated in the past 6 months with Hydroxycarbamide?
b. Of the myelofibrosis patients diagnosed in the last 3 years, how many have received no active treatment in the past 6 months?
Q5. Does your trust participate in any ongoing clinical trials for immune thrombocytopenia (ITP)? If so, can you please provide the name of each trial along with the number of patients taking part?
Q6. Does your trust participate in any ongoing clinical trials for myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part?
